Published By : 12 Jun 2018 | Published By : QYRESEARCH
Over the past few years, bariatric surgeons have been able to bring vast improvements in performing weight loss surgeries that can not only reverse obesity but can also help reverse type II diabetes in patients that are suffering from both the conditions. However, the number of pursuing these surgeries remain significantly low despite it bringing massive improvements in diabetes remission and life quality.
This led to a collaboration between researchers to invent an equally effective but less invasive way of treatment for the reversal of type II diabetes, a treatment that can lead to equally effective benefits as surgery but one that may have a wider set of applications and more appeal. According to the results of a study that has been published in the Nature Materials magazine this week, researchers have reported a successful preclinical study in which an oral agent was used to deliver a substance in rats that could coat the intestine temporarily so as to prevent the contact of nutrient with the intestinal lining in the proximal bowel and avoid blood sugar spikes often seen after meals.
Researchers of the study are envisioning a tablet that can be administered before a meal that can temporarily coat the gut, thus replicating the effects of a surgery. From several years of research on the idea, the researchers have been able to develop a material that can coat the intestinal lining without needing any activation by gastric acid. The team used a substance called sucralfate, which is an FDA approved medicine used to treat gastrointestinal ulcers, as the starting material. The substance was engineered further by the research team to form a material called Luminal Coating of the Intestine or LuCI, which can be made in the form of a dry powder that can be made into a pill.
The use of the pill in rats led to a 47% lowered response to glucose in one hour after the pill was administered. Also, the response was temporary and disappeared after three hours. The long term and short term effects of the pill are being tested in diabetic and obese mice models.